Marie Davidian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6799023/publications.pdf

Version: 2024-02-01

45317 66343 8,678 110 42 90 citations h-index g-index papers 118 118 118 7737 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Estimation of the Odds Ratio in a Proportional Odds Model with Censored Time-Lagged Outcome in a Randomized Clinical Trial. Biometrics, 2023, 79, 975-987.	1.4	1
2	Methods Based on Semiparametric Theory for Analysis in the Presence of Missing Data. Annual Review of Statistics and Its Application, 2022, 9, 167-196.	7.0	0
3	Rejoinder: Estimating vaccine efficacy over time after a randomized study is unblinded. Biometrics, 2022, 78, 848-851.	1.4	1
4	Estimating vaccine efficacy over time after a randomized study is unblinded. Biometrics, 2022, 78, 825-838.	1.4	5
5	Interpretable Dynamic Treatment Regimes. Journal of the American Statistical Association, 2018, 113, 1541-1549.	3.1	46
6	Optimal Two-Stage Dynamic Treatment Regimes from a Classification Perspective with Censored Survival Data. Biometrics, 2018, 74, 1180-1192.	1.4	19
7	Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation. Annals of the American Thoracic Society, 2017, 14, 172-181.	3.2	91
8	The analysis of multivariate longitudinal data: A review. Statistical Methods in Medical Research, 2017, 26, 112-112.	1.5	4
9	Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART. Contemporary Clinical Trials, 2017, 57, 51-57.	1.8	27
10	Dynamic treatment regimes, past, present, and future: A conversation with experts. Statistical Methods in Medical Research, 2017, 26, 1605-1610.	1.5	6
11	Special Issue of Journal of Biopharmaceutical Statistics dedicated to 2016 Trends and Innovations in Clinical Trial Statistics (TICTS) Conference. Journal of Biopharmaceutical Statistics, 2017, 27, 357-357.	0.8	O
12	On Estimation of Optimal Treatment Regimes for Maximizing <i>t</i> -Year Survival Probability. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2017, 79, 1165-1185.	2.2	40
13	Biometrics, JABES and the International Biometric Society. Journal of Agricultural, Biological, and Environmental Statistics, 2017, 22, 221-223.	1.4	1
14	Ten Simple Rules for Effective Statistical Practice. PLoS Computational Biology, 2016, 12, e1004961.	3.2	69
15	Using pilot data to size a twoâ€arm randomized trial to find a nearly optimal personalized treatment strategy. Statistics in Medicine, 2016, 35, 1245-1256.	1.6	19
16	A Placebo ontrolled, Prospective, Randomized Clinical Trial of Polyethylene Glycol and Methylprednisolone Sodium Succinate in Dogs with Intervertebral Disk Herniation. Journal of Veterinary Internal Medicine, 2016, 30, 206-214.	1.6	59
17	Chapter 9: Value search estimators for optimal dynamic treatment regimes. , 2015, , 135-155.		O
18	Using Decision Lists to Construct Interpretable and Parsimonious Treatment Regimes. Biometrics, 2015, 71, 895-904.	1.4	76

#	Article	IF	CITATIONS
19	Properties of Estimators in Exponential Family Settings with Observationbased Stopping Rules. Journal of Biometrics & Biostatistics, 2015, 07, .	4.0	3
20	Estimation After a Group Sequential Trial. Statistics in Biosciences, 2015, 7, 187-205.	1.2	6
21	Discussion of "Combining biomarkers to optimize patient treatment recommendation― Biometrics, 2014, 70, 707-710.	1.4	4
22	The analysis of multivariate longitudinal data: A review. Statistical Methods in Medical Research, 2014, 23, 42-59.	1.5	199
23	Collaboration To Meet the Statistical Needs in the Chemistry Curriculum. Journal of Chemical Education, 2014, 91, 12-12.	2.3	5
24	On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: Sequential trials, random sample sizes, and missing data. Statistical Methods in Medical Research, 2014, 23, 11-41.	1.5	23
25	$\mathbf{Q}\$ and $\mathbf{A}\$ -Learning Methods for Estimating Optimal Dynamic Treatment Regimes. Statistical Science, 2014, 29, 640-661.	2.8	145
26	<tt>SNP_NLMM</tt> : A <i>SAS</i> Macro to Implement a Flexible Random Effects Density for Generalized Linear and Nonlinear Mixed Models. Journal of Statistical Software, 2014, 56, 2.	3.7	4
27	Research Methods for Clinical Trials in Personalized Medicine: A Systematic Review., 2014,, 659-684.		1
28	Building the Biostatistics Pipeline: Summer Institutes for Training in Biostatistics (SIBS). Chance, 2013, 26, 4-9.	0.2	0
29	Moment adjusted imputation for multivariate measurement error data with applications to logistic regression. Computational Statistics and Data Analysis, 2013, 67, 15-24.	1.2	5
30	Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions. Biometrika, 2013, 100, 681-694.	2.4	138
31	Assessing the Causal Effect of Organ Transplantation on the Distribution of Residual Lifetime. Biometrics, 2013, 69, 820-829.	1.4	16
32	The International Year of Statistics: A Celebration and A Call to Action. Journal of the American Statistical Association, 2013, 108, 1141-1146.	3.1	3
33	Mixed model analysis of censored longitudinal data with flexible random-effects density. Biostatistics, 2012, 13, 61-73.	1.5	24
34	Estimating optimal treatment regimes from a classification perspective. Stat, 2012, 1, 103-114.	0.4	177
35	Why Statistics?. Science, 2012, 336, 12-12.	12.6	37
36	Variable selection for covariateâ€adjusted semiparametric inference in randomized clinical trials. Statistics in Medicine, 2012, 31, 3789-3804.	1.6	6

#	Article	IF	Citations
37	A Robust Method for Estimating Optimal Treatment Regimes. Biometrics, 2012, 68, 1010-1018.	1.4	317
38	Improved Doubly Robust Estimation When Data Are Monotonely Coarsened, with Application to Longitudinal Studies with Dropout. Biometrics, 2011, 67, 536-545.	1.4	32
39	A Moment-Adjusted Imputation Method for Measurement Error Models. Biometrics, 2011, 67, 1461-1470.	1.4	19
40	Discussions. International Statistical Review, 2011, 79, 221-223.	1.9	0
41	Doubly Robust Estimation of Causal Effects. American Journal of Epidemiology, 2011, 173, 761-767.	3.4	671
42	Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial. Biostatistics, 2011, 12, 258-269.	1.5	14
43	Demographic and Historical Findings, Including Exposure to Environmental Tobacco Smoke, in Dogs with Chronic Cough. Journal of Veterinary Internal Medicine, 2010, 24, 825-831.	1.6	31
44	Improving efficiency and robustness of the doubly robust estimator for a population mean with incomplete data. Biometrika, 2009, 96, 723-734.	2.4	219
45	Latentâ€Model Robustness in Joint Models for a Primary Endpoint and a Longitudinal Process. Biometrics, 2009, 65, 719-727.	1.4	20
46	Geneâ€Trait Similarity Regression for Multimarkerâ€Based Association Analysis. Biometrics, 2009, 65, 822-832.	1.4	45
47	A model for HCMV infection in immunosuppressed patients. Mathematical and Computer Modelling, 2009, 49, 1653-1663.	2.0	19
48	Nonlinear Models for Longitudinal Data. American Statistician, 2009, 63, 378-388.	1.6	24
49	An Inverse Problem Statistical Methodology Summary. , 2009, , 249-302.		52
50	Covariate adjustment for twoâ€sample treatment comparisons in randomized clinical trials: A principled yet flexible approach. Statistics in Medicine, 2008, 27, 4658-4677.	1.6	228
51	â€~Smooth' inference for survival functions with arbitrarily censored data. Statistics in Medicine, 2008, 27, 5421-5439.	1.6	11
52	"Smooth―Semiparametric Regression Analysis for Arbitrarily Censored Timeâ€ŧoâ€Event Data. Biometrics, 2008, 64, 567-576.	1.4	41
53	Improving Efficiency of Inferences in Randomized Clinical Trials Using Auxiliary Covariates. Biometrics, 2008, 64, 707-715.	1.4	163
54	Modelling HIV immune response and validation with clinical data. Journal of Biological Dynamics, 2008, 2, 357-385.	1.7	47

#	Article	lF	Citations
55	Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data. Statistical Science, 2007, 22, 569-573.	2.8	726
56	Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug and Alcohol Dependence, 2007, 88, S41-S51.	3.2	22
57	Likelihood and pseudo-likelihood methods for semiparametric joint models for a primary endpoint and longitudinal data. Computational Statistics and Data Analysis, 2007, 51, 5776-5790.	1.2	9
58	Estimation and Prediction With HIV-Treatment Interruption Data. Bulletin of Mathematical Biology, 2007, 69, 563-584.	1.9	42
59	Comment: Demystifying Double Robustness: A Comparison of Alternative Strategies for Estimating a Population Mean from Incomplete Data. Statistical Science, 2007, 22, .	2.8	44
60	Smoothing Spline-Based Score Tests for Proportional Hazards Models. Biometrics, 2006, 62, 803-812.	1.4	19
61	Latent-model robustness in structural measurement error models. Biometrika, 2006, 93, 53-64.	2.4	27
62	Semiparametric Estimation of Treatment Effect in a Pretest–Posttest Study with Missing Data. Statistical Science, 2005, 20, 261-301.	2.8	66
63	HIV dynamics: Modeling, data analysis, and optimal treatment protocols. Journal of Computational and Applied Mathematics, 2005, 184, 10-49.	2.0	177
64	Discussion on "Statistical Issues Arising in the Women's Health Initiative". Biometrics, 2005, 61, 933-935.	1.4	0
65	Surgeons? Economic Profiles: Can We Get the ?Right? Answers?. Journal of Medical Systems, 2005, 29, 111-124.	3.6	1
66	Marginal Structural Models for Analyzing Causal Effects of Time-dependent Treatments: An Application in Perinatal Epidemiology. American Journal of Epidemiology, 2004, 159, 926-934.	3.4	113
67	Differential Treatment Benefit of Platelet Glycoprotein Ilb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes. Circulation, 2004, 109, 641-646.	1.6	35
68	Conditional Estimation for Generalized Linear Models When Covariates Are Subject‧pecific Parameters in a Mixed Model for Longitudinal Measurements. Biometrics, 2004, 60, 1-7.	1.4	39
69	Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Statistics in Medicine, 2004, 23, 2937-2960.	1.6	1,163
70	Likelihood and conditional likelihood inference for generalized additive mixed models for clustered data. Journal of Multivariate Analysis, 2004, 91, 90-106.	1.0	7
71	Semiparametric Estimation of Treatment Effect in a Pretestâ€Posttest Study. Biometrics, 2003, 59, 1046-1055.	1.4	55
72	Robust two-stage approach to repeated measurements analysis of chronic ozone exposure in rats. Journal of Agricultural, Biological, and Environmental Statistics, 2003, 8, 438-454.	1.4	7

#	Article	IF	Citations
73	Nonlinear models for repeated measurement data: An overview and update. Journal of Agricultural, Biological, and Environmental Statistics, 2003, 8, 387-419.	1.4	292
74	An estimator for the proportional hazards model with multiple longitudinal covariates measured with error. Biostatistics, 2002, 3, 511-528.	1.5	91
75	Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes. Circulation, 2002, 106, 1470-1476.	1.6	128
76	A Monte Carlo EM algorithm for generalized linear mixed models with flexible random effects distribution. Biostatistics, 2002, 3, 347-360.	1.5	80
77	Estimation of Survival Distributions of Treatment Policies in Two-Stage Randomization Designs in Clinical Trials. Biometrics, 2002, 58, 48-57.	1.4	97
78	A Semiparametric Likelihood Approach to Joint Modeling of Longitudinal and Time-to-Event Data. Biometrics, 2002, 58, 742-753.	1.4	186
79	Robust Twoâ€Stage Estimation in Hierarchical Nonlinear Models. Biometrics, 2001, 57, 266-272.	1.4	18
80	Linear Mixed Models with Flexible Distributions of Random Effects for Longitudinal Data. Biometrics, 2001, 57, 795-802.	1.4	231
81	Consequences of misspecifying assumptions in nonlinear mixed effects models. Computational Statistics and Data Analysis, 2000, 34, 139-164.	1.2	48
82	Estimating Data Transformations in Nonlinear Mixed Effects Models. Biometrics, 2000, 56, 65-72.	1.4	29
83	Correcting for Measurement Error in Individual-Level Covariates in Nonlinear Mixed Effects Models. Biometrics, 2000, 56, 368-375.	1.4	16
84	Differences in Viral Dynamics between Genotypes 1 and 2 of Hepatitis C Virus. Journal of Infectious Diseases, 2000, 182, 28-35.	4.0	214
85	Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocyte Activity Is Inversely Correlated with HIV Type 1 Viral Load in HIV Type 1-Infected Long-Term Survivors. AIDS Research and Human Retroviruses, 1999, 15, 1219-1228.	1.1	120
86	The Effect of Serial Dilution Error on Calibration Inference in Immunoassay. Biometrics, 1998, 54, 19.	1.4	45
87	Estimating the Parameters in the Cox Model When Covariate Variables are Measured with Error. Biometrics, 1998, 54, 1407.	1.4	116
88	Calibration Inference Based on Multiple Runs of an Immunoassay. Biometrics, 1997, 53, 1304.	1.4	9
89	A Two-Step Approach to Measurement Error in Time-Dependent Covariates in Nonlinear Mixed-Effects Models, with Application to IGF-I Pharmacokinetics. Journal of the American Statistical Association, 1997, 92, 436-448.	3.1	58
90	Nonlinear Models for Repeated Measurement Data. Journal of the American Statistical Association, 1997, 92, 789.	3.1	220

#	Article	IF	CITATIONS
91	Bootstrap-Adjusted Calibration Confidence Intervals for Immunoassay. Journal of the American Statistical Association, 1997, 92, 278-290.	3.1	29
92	Testing homogeneity of intra-run variance parameters in immunoassay., 1997, 16, 1765-1776.		9
93	Bootstrap-Adjusted Calibration Confidence Intervals for Immunoassay. Journal of the American Statistical Association, 1997, 92, 278.	3.1	5
94	A Two-Step Approach to Measurement Error in Time-Dependent Covariates in Nonlinear Mixed-Effects Models, With Application to IGF-I Pharmacokinetics. Journal of the American Statistical Association, 1997, 92, 436.	3.1	12
95	Denaturation and Aggregation of Chicken Myosin Isoforms. Journal of Agricultural and Food Chemistry, 1996, 44, 1435-1440.	5.2	29
96	Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 1996, 40, 1360-1365.	3.2	29
97	A note on covariate measurement error in nonlinear mixed effects models. Biometrika, 1996, 83, 801-812.	2.4	32
98	The Effect of Variance Function Estimation on Nonlinear Calibration Inference in Immunoassay Data. Biometrics, 1996, 52, 158.	1.4	27
99	Therapeutic effects of diethylcarbamazine and 3′-azido-3′-deoxythymidine on feline leukemia virus lymphoma formation. Veterinary Immunology and Immunopathology, 1995, 46, 181-194.	1.2	10
100	Assays for recombinant proteins: A problem in non-linear calibration. Statistics in Medicine, 1994, 13, 1165-1179.	1.6	29
101	Population Pharmacokinetic/Pharmacodynamic Methodology and Applications: A Bibliography. Biometrics, 1994, 50, 566.	1.4	75
102	Low serum antibacterial activity coincides with increased prevalence of shell disease in blue crabs Callinectes sapidus. Diseases of Aquatic Organisms, 1994, 19, 121-128.	1.0	45
103	Analysis of repeated measurement data using the nonlinear mixed effects model. Chemometrics and Intelligent Laboratory Systems, 1993, 20, 1-24.	3.5	9
104	Some general estimation methods for nonlinear mixed-effects model. Journal of Biopharmaceutical Statistics, 1993, 3, 23-55.	0.8	67
105	The nonlinear mixed effects model with a smooth random effects density. Biometrika, 1993, 80, 475-488.	2.4	191
106	Some Simple Methods for Estimating Intraindividual Variability in Nonlinear Mixed Effects Models. Biometrics, 1993, 49, 59.	1.4	54
107	Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 529-556.	0.6	103
108	Regression and calibration with nonconstant error variance. Chemometrics and Intelligent Laboratory Systems, 1990, 9, 231-248.	3.5	55

#	Article	IF	CITATIONS
109	Estimation of variance functions in assays with possibly unequal replication and nonnormal data. Biometrika, 1990, 77, 43-54.	2.4	20
110	Variance functions and the minimum detectable concentration in assays. Biometrika, 1988, 75, 549-556.	2.4	76